As we continue to combat the pandemic, America’s biopharmaceutical industry is working around the clock in unprecedented partnerships to manufacture COVID-19 vaccines, reaching billions of doses by the end of the year. Vaccination rates and willingness to receive a vaccine among Americans are also at a high, where half of all adults in the U.S. have received at least one dose of the COVID-19 vaccine.
Americans recognize that COVID-19 vaccines are integral to controlling the spread of coronavirus in the United States, and they appreciate the cautious approach to assessing vaccine safety.
- 88% of Americans support the caution demonstrated by the FDA and CDC, and 58% said that FDA and CDC caution around vaccine safety has made them more confident in the vaccines.
- According to Gallup, 74% of adults are either willing to or have already been vaccinated against coronavirus, with 50% of adults having received at least one dose of the vaccine.
- Continued willingness to be vaccinated is also likely driven by the majority of Americans (57%) who state that they trust the advice of the CDC.
- When it comes to the impact of new coronavirus variants on vaccinations, attitudes about the importance of vaccinations in the U.S. are linked to perceptions of the potential threat posed by outbreaks. According to Pew, 58% of Americans believe that the spread of new variants makes it more important for a large majority of the public to get vaccinated.
Americans appreciate biopharmaceutical leadership in the research and development of COVID-19 vaccines.
- American companies, as the engine of the unique innovation ecosystem, have led in discovery and development of a robust vaccine supply, and these efforts have not gone unnoticed. 87% of Americans agree the coronavirus pandemic has shown the important role drug companies have in research and development for discovering new treatments, cures and vaccines.
- The biopharmaceutical industry continues to work around the clock to scale production of COVID-19 vaccines, as well as continue to test new vaccines and existing therapies to treat coronavirus.
- Industry has formed unprecedented partnerships to increase scale and overall production with the collective goal of ending the pandemic. Current forecasts estimate that the number of vaccines produced to date will increase by more than 600% in the next 8 months.
With more Americans showing willingness to receive a coronavirus vaccine, Americans are counting on a strong U.S. biopharmaceutical industry to meet the growing demand. Now, more than ever, we need to ensure that we continue investing in this critical innovation ecosystem that supports our pandemic response. The industry is working nonstop to ramp up vaccine production while continuing to innovate around solutions to help end the pandemic.
Mark Keida
Mark Keida, Ph.D. is Vice President in Public Affairs. He leads PhRMA’s message and polling team, supporting advocacy communications, paid media campaigns and earned media. Mark specializes in using data to guide narrative, campaign strategy and tactics.
Mark Keida
Why smart vaccine policy matters
New study: HPV vaccination helps prevent cervical cancer deaths
New research reinforces the importance of hepatitis B vaccination at birth
World Immunization Week: Putting preventable diseases in the past
Survey confirms too many insured Americans face barriers to reliable health care
ICYMI: Measles resurgence could cost U.S. nearly $8 billion over five years
Americans believe U.S. pharma leadership needs to be protected
Why shifting childhood vaccines to “shared clinical decision-making” puts kids at risk
50-state poll says Americans are concerned that hospital markups hurt patients
Changes to America’s childhood vaccine schedule fail to protect our nation's kids
New study: Measles setbacks harm health and America’s economy
Why the hepatitis B vaccine matters
Vaccines and autism: Decades of scientific evidence find no link
Why the vaccine injury program matters
Recognizing the importance of vaccination for American health and security
Answering common questions on mRNA technology
What to know about vaccine ingredients: Aluminum and thimerosal
World Immunization Week: Highlighting the importance of vaccines for public health
Health care practitioners sound the alarm on middlemen-imposed barriers to patient care, need for policy change
What you need to know: Measles and the MMR vaccine
Improved treatments continue to lead to declining cancer mortality rates in the U.S.
Preventing and fighting disease: A look at the biopharmaceutical progress made for patients in 2024
Recognizing the value of disease prevention with Dr. Len Friedland from GSK
Leveraging the power of vaccines to prevent antimicrobial resistance
From the emergency department to the CDC Advisory Committee: Key takeaways from ACIP’s recent meeting
New PES survey: Out-of-pocket costs lead key health care priorities ahead of the November election
Americans speak out on health insurance barriers and need for policy change, according to the latest Patient Experience Survey
The Patient Perspective: Vaccines
Where voters stand ahead of the election
Key voter insights two months from Election Day
How to protect your children’s health this school year
Voters across all 50 states want state policymakers to focus on health insurance and PBM practices
New Report: Vaccines continue to drive improved health outcomes
New 50-state poll Americans want to hold health insurers and PBMs accountable for high out-of-pocket costs and other practices
Showcasing the promise of biopharma at ASCO 2024
ICYMI: What patients care about this election year
Key election year voter insights
ICYMI: Voter priorities this election season
World Vaccine Congress: Building on vaccine success
Voter insights: Four things to know
New poll: Americans agree that expanding the TRIPS waiver will harm U.S. global manufacturing and innovation leadership
WHO Pandemic Agreement offers opportunities and risks for American innovators
New Report: 1,600 cancer treatments and vaccines in clinical development
One year to Election Day: Four voter priorities to watch
New poll shows strong bipartisan support for PBM reform
What you should know about protecting your health this fall
Navigating the Patient Experience Survey: Protecting Lifelines to Access and Innovation
Three things to know from the latest Patient Experience Survey
A conversation with Dr. Mike Ybarra on the current state of COVID-19
4 Things to know about PhRMA’s new 50-state poll
Americans want state policymakers to lower out-of-pocket costs
What they are saying: Experts reinforce that TRIPS waiver expansion is harmful and unnecessary
PhRMA provides comments and testimony to USITC investigation on COVID-19 medicines and the TRIPS Agreement
Key Trends: Patient experience data reveal how insurers and middlemen impose barriers in health care
Celebrating the success of the COVID-19 vaccines, and looking to the future
What we’ve learned from three years of fighting COVID-19
In their own words: Insured Americans support policy reforms that address access and affordability concerns
In their own words: Financial barriers exacerbate access challenges for insured Americans
Word of the Month: What is TRIPS?
What you should know about RSV
In their own words: Insured Americans struggle to navigate complex coverage
Word of the Month: Long COVID
Protecting against influenza: A conversation with David Ross, Vice President, Commercial Operations, North America, CSL Seqirus
Mental Illness Awareness Week – A time for reflection
Partnerships are driving global COVID-19 treatment access
Navigating the patient experience: Burdens and barriers standing between patients and their care
New survey: Voters seriously concerned about fine print in reconciliation bill
Survey Says: Prescription drug prices are not fueling inflation concerns for Americans
ICYMI: PhRMA’s Ubl pens op-ed on IP waiver for COVID-19 technologies
Polling continues to show voters reject so-called Medicare “negotiation” once they learn about consequences for patients
3 things voters are concerned about when it comes to their health care coverage
Patients support state action requiring PBMs and insurers to share savings and cap costs for medicines
New poll shows voters sounding the alarm on health insurance companies and PBMs
Study finds insurance barriers disproportionately burden patients with chronic illness
5 public opinion polling trends to watch
The patient experience: Uncovering the barriers to care for insured Americans
The patient experience: Insurance barriers continue to impede access to health care, especially among the country’s underserved
New Data: COVID-19 vaccine global production capacity projected to exceed 20 billion doses this year
What you need to know about newly authorized COVID-19 antiviral treatments
Guest Blog: COVID-19 vaccines are the key to keeping kids healthy
New poll of all 50 states and 435 Congressional Districts shows perils of so-called Medicare “negotiation”
Navigating the patient experience in the time of COVID-19
Global COVID-19 vaccination matters now and for the future
Insurance design barriers can impact patient adherence and can lead to poor health outcomes
ICYMI: PhRMA CEO speaks at STAT Summit about government price setting
Three things to know about so-called Medicare negotiation polling
Understanding breakthrough COVID-19 infections
The patient experience: Insurance design hurdles lead to access issues for too many Americans
The patient experience: Out-of-pocket costs are driving patients affordability and access challenges
New poll shows Americans reject Medicare negotiation once they learn more about the policy
What is Kaiser Family Foundation up to?
New report shows 3 in 10 Americans that have insurance still face a financial barrier to care
The important role of antivirals in the fight against COVID-19
A year and a half later: The biopharmaceutical industry remains committed to beating COVID-19
Recognizing National Immunization Awareness Month
Recent polling misrepresents public support for Medicare “negotiation”
Driving further innovation is critical to global vaccine equity
Myth vs. fact: Polling and Medicare “negotiation”
Supporting country readiness to boost global vaccine access
Ensuring global vaccine equity requires eliminating trade and regulatory barriers
Setting the record straight: Addressing common misconceptions about the COVID-19 vaccine
Increasing global access to vaccines by optimizing production
Guest post: Retired medics return to the field to take on vaccine delivery and disaster relief
Guest Post: A patient’s story of the long-term health impacts of COVID-19
Dose sharing as a part of the COVID-19 global vaccine equity strategy
Promoting global vaccine equity while protecting innovation
Data shows voters strongly support protecting access to their medicines
Data shows COVID-19 vaccines are creating a pathway to a strong U.S. recovery
Americans 12 years of age and older are eligible for COVID-19 vaccines
ICYMI: PhRMA president and CEO Stephen J. Ubl joins other industry leaders for a conversation on COVID-19 vaccines with Axios
Supporting India during the devastating coronavirus surge
New polling shows Americans are sounding the alarm on the TRIPS IP waiver
Four solutions Americans support to make health care more affordable
PhRMA CAREs Grant request for proposals: Addressing inequities in access to COVID-19 testing, therapeutics and vaccines
Ron Busby, Sr., President and CEO of the U.S. Black Chambers, Inc. on improving vaccine confidence in community
Patient safety is at the heart of COVID-19 vaccine R&D
Diversifying clinical trials and fighting disease requires equity and trust
Data shows that keeping a strong biopharmaceutical industry is important to Americans
Building confidence in the COVID-19 vaccine through education
ICYMI: WSJ showcases breakthrough science of COVID-19 vaccines and implications for future medicines
Intellectual property is the key to vaccine development, manufacturing and technology sharing
Coming together to fight COVID-19: A conversation with Paul Perreault, CEO and Managing Director of CSL
Fighting variants of COVID-19
Top five issues voters want addressed in the administration’s first 100 days
Growing trend: Increased vaccine confidence
The latest misleading “poll” on drug pricing
Election insights: Common ground areas to address Americans’ health care concerns
Election insights: Voter priorities in the states
Insights from the election: Meeting voters where they are on health care
Guest post: How COVID-19 underscores the importance of public confidence in vaccines
Deep dive: The issues that drove the 2020 vote
Understanding the emergency use authorization process for COVID-19 vaccines
Voters want to address the real drivers of health care costs for patients and the system
Three things you should know about recent health care polling
Flu Season 2020: Why it’s time to talk to your doctor today about getting a flu shot
Coming together to fight COVID-19: A conversation with Albert Bourla, Chairman & CEO of Pfizer, Inc.
Coming together to fight COVID-19: A conversation with Paul Hudson, CEO of Sanofi
Supporting access to vaccines for Part D beneficiaries
New report shows more than 400 medicines and vaccines in development to tackle infectious diseases, including COVID-19
PhRMA’s Lori Reilly joined CSG to discuss the industry’s response to COVID-19 and what it means for states
How biopharmaceutical researchers are ensuring COVID-19 vaccines will be safe and effective
Guest Post: From lab to jab: Vaccine development to prevent COVID-19
What scientific experts are saying about vaccine safety
New report shows nearly 260 vaccines in development, including dozens for COVID-19
ICYMI: Continued biopharmaceutical action on COVID-19
Why vaccines work in the fight against measles and other infectious diseases
Medicare Monday: Helping beneficiaries access vaccines
New report and event examine the new era of vaccines
Medicare Monday: Strengthening access to vaccines for seniors
Data shows that Americans are relying on vaccines to get us through the pandemic
Vaccines
Polling
Data shows that Americans are relying on vaccines to get us through the pandemic
Data shows that Americans are relying on vaccines to get us through the pandemic